Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies

NCT01943851 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01943851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01943851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
May 14, 2014
Completion date
April 30, 2020
Enrollment
111 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms